|
y********o
发帖数: 1588 | 2 昨天盘后36.3买的，早上盘前38.3卖了。lol，谢谢 |
|
v*****k
发帖数: 7798 | 3 ZT from hutong9:
导读：专业投资人阿尔图切尔(James Altucher)在MarketWatch撰文大胆预言，现在已
经成为世界上市值最大企业的苹果还将会很快成为第一家市值上万亿，乃至两万亿美元
的公司。
以下即阿尔图切尔的评论文章全文：
不久前，在做一次电视评论时，我犯了个错误。我当时说，苹果将成为世界上第一
家市值达到1万亿美元的公司。当晚我回家的时候，我就遇到了一帮还在闲逛的朋友：
“嘿，太没想象力了吧？为什么到1万亿就为止了，为什么苹果不能成为世界上第一家2
万亿美元的公司？”
听上去，似乎他们是对的。
苹果(AAPL)将成为世界上第一家2万亿美元的公司。目前，苹果的市值大约是3230
亿美元。
“万亿”这样一个字眼会让人感到害怕。就像五十年前，盖蒂(J. Paul Getty)就
曾经说过：“今天的1万亿美元早不是过去的1万亿美元了。”他对于当时那些发现自己
过了二十年才刚刚走出大萧条的美国人，或者是五十年后的今天的美国人的感受，也太
不在意了，他的幸福处方当中不仅仅只有自家的花园，一条干净的裤子，一个大学学位
，甚至还要有1万亿美元，而且这还无法满足胃口... 阅读全帖 |
|
O****s
发帖数: 463 | 4 下面这几个上周暴跌，能否请肥猫侠帮模拟计算下
DNDN – Dendreon Corporation
SNE – SONY CORP
SLF – Sun Life Fincl Inc
MED – Medifast Inc
DRIV – Digital River, Inc.
ELON – Echelon Corporation
JOE – ST JOE CORP
DGI – Digitalglobe Inc
RGR |
|
O****s
发帖数: 463 | 5 下面这几个上周暴跌，能否请肥猫兄帮模拟计算下
DNDN – Dendreon Corporation
SNE – SONY CORP
SLF – Sun Life Fincl Inc
MED – Medifast Inc
DRIV – Digital River, Inc.
ELON – Echelon Corporation
JOE – ST JOE CORP
DGI – Digitalglobe Inc
RGR |
|
O****s
发帖数: 463 | 6 下面这几个上周暴跌，能否请肥猫兄帮模拟计算下
DNDN – Dendreon Corporation
SNE – SONY CORP
SLF – Sun Life Fincl Inc
MED – Medifast Inc
DRIV – Digital River, Inc.
ELON – Echelon Corporation
JOE – ST JOE CORP
DGI – Digitalglobe Inc
RGR |
|
k********n
发帖数: 18523 | 7 ☆─────────────────────────────────────☆
kbrhouston (石油工人-一切MM都是普赛，纸老虎) 于 (Sat Nov 5 22:33:29 2011, 美东) 提到:
1来便于查阅
2来便于老牛清水（怕误删）
3便于顶进十大，壮大声势，繁荣古板
4减少肥猫工作（否则他需要花精力查看大家的所有请求贴）
谢谢大家
☆─────────────────────────────────────☆
MB80528 (肥猫(Contrarian)[食MM而肥]) 于 (Mon Nov 7 23:08:16 2011, 美东) 提到:
要最新预测的，
请在此报名股票符号。
打算提供２０到３０个预测。
由最先报名的股票符号开始。
☆─────────────────────────────────────☆
fockugcd (fockugcd) 于 (Mon Nov 7 23:09:47 2011, 美东) 提到:
胖肥猫，是不是永久免费的：）？？？？？？？？？？？？？？？
☆────────────────────... 阅读全帖 |
|
|
s*******t
发帖数: 335 | 9 Financing Options for Small Biotechnology Companies
If you are an investor in biotechnology companies, periodic financings are a
fact of life and necessary for the company to survive and be successful.
Nevertheless, there is a belief among some investors that anytime a Company
raises money through issuing shares, it dilutes and harms existing
shareholders. However, issuing new shares is not always a bad thing for
existing shareholders. The willingness of new investors to put money into a
company... 阅读全帖 |
|
J**S
发帖数: 25790 | 10 我知道是集体诉讼，可能捞点钱，但是到底怎么回事？ |
|
r*****t
发帖数: 7278 | 11 Apple Inc. AAPL 498.53 -3.83 (-0.76%) -1.00 498.53 (498.53
) -128.53 -25.78% +3.83 -25.78%
Barrick Gold Corp. (USA) ABX 19.58 +0.51 (2.67%)
Aluminum Corp. of China... ACH 8.68 +0.35 (4.20%) 1,000.00
7,750.00 8,680.00 +930.00 +12.00% +350.00 12.00%
ProShares Ultra Silver... AGQ 23.13 +0.17 (0.74%)
American Intl. Group Inc AIG 47.08 +0.36 (0.7... 阅读全帖 |
|
n*********e
发帖数: 25274 | 12 经济确实不咋的,象今天那个Dendreon公司,居然跌了70%.PhaseIII的药去年刚通过,可
惜卖不出去...只能怪病人太穷,保险公司太抠... |
|
b*******z
发帖数: 14 | 13 我有一个做生物研究的朋友对在西雅图研发部门的Scientist职位很感兴趣，不知可否
帮忙内部投个简历？ 请站内联系，多谢了！ |
|
s***i
发帖数: 10182 | 14 虽然不太牛逼但是还行吧
你自己搜搜看 西雅图的生物公司还是可以的
corixa Dendreon ZymoGenetics Trubion
而且生物是这里重点发展的产业 |
|
m*******a
发帖数: 130 | 15 Dendreon? Anyway人生新的开始，是好事。
为什么不签package? 你要告他吗？ |
|
f******s
发帖数: 288 | 16 据说下面这个‘provenge’会成为以后的blockbuster之一
http://www.dendreon.com/pipeline/sipuleucel_t/
他家根其他人的产品不太一样，用的是病人自身产生的抗体，总之是trick 病人自身的
免疫系统attack肿瘤的。
我不是研究免疫的，很感兴趣那些以肿瘤为目标的antibody（据说pfizer有一个已经上
市的了？）毕竟个体的差别很大，依赖肿瘤细胞表面特异的抗原就可以么？可以target
的选择多吗？
大家觉得这个方向的前景好么？ |
|
c*********t
发帖数: 340 | 17 Dendreon
They isolate dendritic cells from the patient and stimulate with PAP (
prostate associated phosphate or something, a tumor associated antigen), and
infuse back
the median survival time could be prolonged by four months
then tumor cells expressing low levels of PAP would come up
75K for one round of treatment
really expensive
but it works |
|
A******y
发帖数: 2041 | 18 You guys never heard of a company called Dendreon? Spin of old idea, the
best one barely approved by FDA only extend life by 6 month for prostate
cancer. |
|
|
j****x
发帖数: 1704 | 20 http://blog.sina.com.cn/s/blog_77f807030101ig90.html
肿瘤免疫疗法是当前肿瘤治疗领域最具前景研究方向之一，各大药企纷纷寻求与其他公
司合作研发肿瘤免疫相关治疗方法。初步的临床试验结果表明其治疗有效率非常高，
Science杂志也将肿瘤免疫疗法评为2013年十大科学突破第一位。
本文首先介绍肿瘤免疫疗法在肿瘤治疗中的地位，然后是作用机制和具体分类，已经上
市或在研药物、市场预测，最后列举各公司之间的收购合作及国内部分参与相关研发的
公司。
1肿瘤治疗发展历程
1.1传统疗法
包括手术切除、化疗、放射线治疗。其具有局限性：手术切除的方式常因为癌细胞入侵
蔓延到邻近组织或远端转移而效果有限；化疗受限于对体内其他正常组织的毒性；放疗
辐射也同样会对正常组织造成伤害。传统疗法都是对身体有极大负担，并且在发生恶性
转移后，无论是何种方式都是很难彻底治愈。
1.2靶向疗法
20世纪末出现的靶向疗法是在细胞分子水平上，针对已经明确的致癌位点来设计相应的
治疗药物，药物进入体内会特异地选择致癌位点来相结合发生作用，使肿瘤细胞特异性
死亡，而不会伤及肿瘤... 阅读全帖 |
|
|
n*******r
发帖数: 425 | 22 Mon
Earnings: Shaw Group Inc (SHAW), Allstate Corp (ALL), Anadarko Petroleum
Corp (APC), Leap Wireless International Inc (LEAP)
Economic Data: Chicago Purchasing Manager, Dallas Fed Manf. Activity
Tues
Earnings: Archer-Daniels-Midland Co (ADM), CME Group Inc (CME), Checkpoint
Systems (CKP), Baker Hughes (BHI), Pfizer Inc (PFE), Sirius XM Radio (SIRI),
Williams Cos Inc (WMB), JDS Uniphase Corp (JDSU), Fiserv Inc (FISV),
OpenTable (OPEN), Valero Energy Corp (VLO), MEMC Electronic Materials I... 阅读全帖 |
|
X*****s
发帖数: 2767 | 23 YMYD。这里也是回答samma的问题。
DNDN的股价直接和药PROVENGE的销售额相关，所以直接去公司网站查前3个quarter的ER，
1.Net revenue for the quarter ended June 30, 2011 was $49.6 million
2.Net revenue for the quarter ended September 30, 2011 was $64.3 million
Announced approximately $66 million in gross PROVENGE sales in the third
quarter
3. Product revenue for the fourth quarter of 2011 was $77 million
Net income in the fourth quarter of 2011 was $38.1 million or $0.26 per
share, compared to a net loss of $91.8 million, or $0.64 per share, ... 阅读全帖 |
|
p**********r
发帖数: 108 | 24 ☆─────────────────────────────────────☆
pray2008 (stock888) 于 (Sun Apr 11 22:47:41 2010, 美东) 提到:
http://gwestrookitraders.com/fdadates.html
☆─────────────────────────────────────☆
tanmaomao (坛猫猫) 于 (Mon Apr 12 10:03:52 2010, 美东) 提到:
Biotech Stocks Facing FDA Approval From April - October 2010
Cell Therapeutics (CTIC)
Drug/indication: Pixantrone for non-Hod1gkin's lymphoma
Approval decision date: April 23
An FDA advisory panel held on March 22 voted 9-0 to recommend against
approval of ... 阅读全帖 |
|
w***y
发帖数: 2537 | 25 【 以下文字转载自 Stock 讨论区 】
发信人: ll111 (Stealth), 信区: Stock
标 题: Events and ER for week August 2-6
发信站: BBS 未名空间站 (Sun Aug 1 22:47:17 2010, 美东)
Monday, Aug. 2
10 a.m.: ISM Manufacturing index on business activity in July, released by
the Institute for Supply Management.
10:15 a.m. Federal Reserve Chairman Ben Bernanke speaking on "challenges for
the economy and state governments."
4 p.m. Treasury Secretary Timothy Geithner speaking on the next steps for
financial reform.
Tuesday, Aug. 3
8:30 a.m.: P... 阅读全帖 |
|
f**********g
发帖数: 2252 | 26 anyone familar?
Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit
on Tuesday, March 1
1 days 6 hours 27 minutes ago - EUR via Comtex
PR Newswire EuropeNeoStem, Inc. , an international biopharmaceutical company
with operations in the U.S. and China, announced today that Dr. Robert
Preti, PhD, President and Chief Scientific Officer of Progenitor Cell
Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc., has been asked
to present on Tuesday, March 1, 2011 at the 6th ... 阅读全帖 |
|
f**********g
发帖数: 2252 | 27 anyone familar?
Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit
on Tuesday, March 1
1 days 6 hours 27 minutes ago - EUR via Comtex
PR Newswire EuropeNeoStem, Inc. , an international biopharmaceutical company
with operations in the U.S. and China, announced today that Dr. Robert
Preti, PhD, President and Chief Scientific Officer of Progenitor Cell
Therapy ("PCT"), a wholly-owned subsidiary of NeoStem, Inc., has been asked
to present on Tuesday, March 1, 2011 at the 6th ... 阅读全帖 |
|
w******i
发帖数: 1476 | 28 24% increase
LINCOLNSHIRE, Ill. (AP) -- BioSante Pharmaceuticals Inc. said Thursday its
potential pancreatic cancer treatment met key goals in a midstage study.
The company's stock surged 32 cents, or 16 percent, to $2.35 in premarket
trading.
The company said a newly published study showed the vaccine increased the
median survival rate of patients by more than 25 percent to 24.8 months. The
results were published in the February issue of the Annals of Surgery and
involved 60 patients undergoing... 阅读全帖 |
|
w******i
发帖数: 1476 | 29 24% increase
LINCOLNSHIRE, Ill. (AP) -- BioSante Pharmaceuticals Inc. said Thursday its
potential pancreatic cancer treatment met key goals in a midstage study.
The company's stock surged 32 cents, or 16 percent, to $2.35 in premarket
trading.
The company said a newly published study showed the vaccine increased the
median survival rate of patients by more than 25 percent to 24.8 months. The
results were published in the February issue of the Annals of Surgery and
involved 60 patients undergoing... 阅读全帖 |
|
y*****l
发帖数: 5997 | 30 银杏，这是pre-FDA run吗？有几成把握？
Dendreon(DNDN)
Drug/indication: Provenge for prostate cancer (Atlanta manufacturing
expansion)
Approval decision date: Aug. 28, 2011 |
|
b**********k
发帖数: 1262 | 31 好长， 居然看完了
“Don't fall for the trick. Whenever you hear claims that a company is being
sunk by naked short selling, the
truth is that poor management performance is the probable culprit.
” |
|
p********e
发帖数: 1960 | 32 http://seekingalpha.com/article/287381-the-two-very-best-biotec
The market correction has been a gift.
After combing through low-flyer biotechs for over one year, I am convinced
that the two very best biotechs under $3/share are: BioSante Pharmaceuticals
(BPAX) and Antares Pharma (AIS). If I was pressed to add a third stock to
my list, it would be AEterna Zentares (AEZS), but for now I will stick with
only two. The basis for my researched conclusion is as follows:
BioSante
BioSante recently gave... 阅读全帖 |
|
y*****l
发帖数: 5997 | 33 http://www.thestreet.com/_yahoo/story/11215926/1/biotech-calend
Updated with corrected FDA approval decision date for Roche's melanoma drug
Zelboraf. It's Oct. 28, 2011, not Nov. 11, 2011, as previously reported.
BOSTON (TheStreet) -- The 2011 FDA drug approval calendar has been updated
and extended through the first quarter of 2012.
For easier reference, this regulatory calendar is organized in chronological
order based on the drug approval decision date. Information on pending FDA
advisory pan... 阅读全帖 |
|
v**********m
发帖数: 5516 | 34 最近该公司的案子
New Cases & Investigations
Securities Class Actions Against Miller Energy Resources
Securities Class Action Against SinoTech Energy Limited (CTE)
Securities Class Action Against Dendreon Corporation
- Lead Plaintiff Deadline October 4, 2011
Securities Class Action Lawsuit Against Motricity
Securities Fraud Class Action Against JBI, Inc.
Milberg LLP and Kim Orr Barristers P.C. Announce
Investigation of Sino-Forest Corporation
Investigating Citibank for Improper Fees Relating to Balance ... 阅读全帖 |
|
f**********g
发帖数: 2252 | 35 Dendreon (DNDN_) target cut at Goldman. Shares of DNDN now seen reaching $14
. Company needs to improve execution with Provenge. Buy rating.
目标下调，股票上涨。 |
|
y*****l
发帖数: 5997 | 36 11:55 Do you think there is > 50% chance someone buys HGSI in next 12 mos.?
Yes
( 68% )No
( 32% )
Thursday October 20, 2011 11:55
11:56 adam feuerstein: Hello! Welcome to the October edition of Biotech
Stock Live Chat.
Thursday October 20, 2011 11:56 adam feuerstein
12:02 adam feuerstein: hi everyone
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuerstein: I'll get started in a minute or so, let folks log in
.
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuers... 阅读全帖 |
|
p********m
发帖数: 93 | 37 Goldman comment
November 16, 2011
COMMENT
Dendreon Corporation (DNDN) $7.21
Positive takeaways from a call on Provenge with a leading urologist
We hosted a call today with a urologist, who is a leader in the Large
Urology Group Practice Associations (LUGPAs; 10+ urologists), to discuss the
evolving prostate cancer landscape, with a focus on Provenge. LUGPA
represent nearly 20% of the US urologists. We have previously identified
the LUGPAs as a key target for potentially increasing Provenge use g... 阅读全帖 |
|
v**********m
发帖数: 5516 | 38 烟幕弹又来了，不知MM能拉到什么价位。
GlaxoSmithKline (GSK) And Biogen Idec (BIIB) Possible Candidates To Acquire
Human Genome Sciences (HGSI), Says Senior Analyst At Piper Jaffray; Read
More About This Prospect And Others In The Biotech Space In This Exclusive
Interview
November 21, 2011 - The Wall Street Transcript has just published
Biotechnology and Pharmaceuticals Report offering a timely review of the
Biotechnology sector. This Special Report contains expert industry
commentary through in-depth interviews w... 阅读全帖 |
|
